...
首页> 外文期刊>Journal of Clinical Oncology >Autologous stem-cell transplantation for non-Hodgkin's lymphomas: the role of graft purging and radiotherapy posttransplantation--results of a retrospective analysis on 120 patients autografted in a single institution.
【24h】

Autologous stem-cell transplantation for non-Hodgkin's lymphomas: the role of graft purging and radiotherapy posttransplantation--results of a retrospective analysis on 120 patients autografted in a single institution.

机译:非霍奇金淋巴瘤的自体干细胞移植:移植后移植物清除和放疗的作用-回顾分析单个机构中120例患者的结果。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

PURPOSE: To analyze retrospectively survival and prognostic factors of patients with non-Hodgkin's lymphoma (NHL) autografted from 1979 to 1995 in a single institution. PATIENTS AND METHODS: A total of 120 patients, 64 with aggressive and 56 with low-grade NHL, were autografted. The carmustine (BCNU), etoposide, cytarabine, and melphalan (BEAM) regimen was used in 104. The autograft was marrow in 101 patients. Marrow was purged in vitro by mafosfamide for 63 patients (adjusted dose [AD] in 32; unique dose [UD] in 31); 27 patients received a CD34+-selected graft. Following intensification, 45 patients received additional radiotherapy on previous sites of involvement. RESULTS: Outcome at 5 years for patients transplanted with low-grade NHL in first complete remission (CR1), in first partial remission (PR1), and in second complete remission (CR2) or beyond showed an event-free survival (EFS) of 75% +/- 12%, 46% +/- 18%, and 57% +/- 24%, a relapse incidence (RI) of 21% +/- 12%, 49% +/- 19%, and 43% +/- 25%, and a transplant-related mortality (TRM) of 5% +/- 5%, 10% +/- 7%, and 0%, respectively. For patients with aggressive NHL transplanted in CR1, in PR1, in CR2 or beyond, and in resistant relapse or in primary refractory disease, the EFS was of 73% +/- 9%, 58% +/- 19%, 29% +/- 16%, and 10% +/- 9%, the RI 22% +/- 9%, 14% +/- 9%, 77% +/- 18%, and 66% +/- 20%, and the TRM 6% +/- 6%, 32% +/- 21%, 11% +/- 10%, and 71% +/- 22%, respectively. In patients autografted upfront in first remission, additional radiotherapy was associated with a higher EFS, in univariate (P = .03) and multivariate analysis (P = .02, relative risk [RR] = .021). The role of graft purging with mafosfamide on the outcome reflected by the dose of colony-forming unit-granulocyte-macrophage (CFU-GM) per kilogram infused postpurging was assessed by univariate analysis: patients in first remission who received lower doses of CFU-GM had a lower RI and a higher EFS. CONCLUSION: This retrospective analysis suggests that marrow purging and posttransplant radiotherapy improve the outcome of patients with NHL autografted in first remission.
机译:目的:回顾性分析1979年至1995年在单个机构中自体移植的非霍奇金淋巴瘤(NHL)患者的生存率和预后因素。患者与方法:共移植120例患者,其中64例具有侵略性,而56例具有低度NHL。 104例使用卡莫司汀(BCNU),依托泊苷,阿糖胞苷和美法仑(BEAM)方案。101例患者接受了自体骨髓移植。莫夫沙酰胺在体外清除了63例患者的骨髓(调整剂量[AD]为32;独特剂量[UD]为31); 27例患者接受了CD34 +选择的移植物。强化治疗后,有45名患者在以前的受累部位接受了额外的放射治疗。结果:初次完全缓解(CR1),第一次部分缓解(PR1)和第二次完全缓解(CR2)或以后的低级NHL移植患者在5年后的结果显示无事件生存(EFS)为75%+/- 12%,46%+/- 18%和57%+/- 24%,复发率(RI)为21%+/- 12%,49%+/- 19%和43 +/- 25%,与移植相关的死亡率(TRM)分别为5%+/- 5%,10%+/- 7%和0%。对于在CR1,PR1,CR2或更高,抗药性复发或原发性难治性疾病中移植了侵袭性NHL的患者,EFS为73%+/- 9%,58%+/- 19%,29%+ /-16%和10%+/- 9%,RI 22%+/- 9%,14%+/- 9%,77%+/- 18%和66%+/- 20%,以及TRM分别为6%+/- 6%,32%+/- 21%,11%+/- 10%和71%+/- 22%。在首次缓解中自体移植的患者中,单因素(P = .03)和多因素分析(P = .02,相对危险度[RR] = .021),额外的放疗与较高的EFS相关。通过单因素分析评估了每清洗一次后注入的每千克所注入的集落形成单位-粒细胞-巨噬细胞(CFU-GM)的剂量,反映出用草磷酰胺进行的移植物清除对结局的作用:通过首次缓解的患者接受了较低剂量的CFU-GM具有较低的RI和较高的EFS。结论:这项回顾性分析表明,骨髓清除和移植后放疗可改善首次缓解时自体移植的NHL患者的预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号